T Acute Lymphoblastic Leukemia

21 clinical trials · Condition

Record	Firm	Date
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL (NCT04582487)	Gruppo Italiano Malattie EMatologiche dell'Adulto	2021-05-19
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL (NCT04620655)	Min Xiang	2020-11-15
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (NCT04128501)	M.D. Anderson Cancer Center	2020-05-05
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies (NCT05127135)	Fundamenta Therapeutics, Ltd.	2020-01-22
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984)	University of Southern California	2018-05-09
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT03007147)	Children's Oncology Group	2017-08-08
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (NCT02484430)	National Cancer Institute (NCI)	2017-04-06
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia (NCT02767934)	University of Washington	2017-01-13
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (NCT02763384)	Washington University School of Medicine	2016-12-02
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT00501826)	M.D. Anderson Cancer Center	2007-07-11
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (NCT00408005)	National Cancer Institute (NCI)	2007-01-30

Track T Acute Lymphoblastic Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.